Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 329

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant

Open access
Chapuis, Aude G., Egan, Daniel N., Bar, Merav, Schmitt, Thomas M., McAfee, Megan S., Paulson, Kelly G., Voillet, Valentin, Gottardo, Raphael, Ragnarsson, Gunnar B., Bleakley, Marie, Yeung, Cecilia C., Muhlhauser, Petri, Nguyen, Hieu N., Kropp, Lara A., Castelli, Luca, Wagener, Felecia, Hunter, Daniel, Lindberg, Marcus, Cohen, Kristen, Seese, Aaron, McElrath, M. Juliana, Duerkopp, Natalie, Gooley, Ted A., Greenberg, Philip D.·2019·Nature Medicine

Abstract

Relapse after allogeneic hematopoietic cell transplantation (HCT) is the leading cause of death in patients with acute myeloid leukemia (AML) entering HCT with poor-risk features1–3. When HCT does produce prolonged relapse-free survival, it commonly reflects graft-versus-leukemia effects mediated by donor T cells reactive with antigens on leukemic cells4. As graft T cells have not been selected for leukemia specificity and frequently recognize proteins expressed by many normal host tissues, graft-versus-leukemia effects are often accompanied by morbidity and mortality from graft-versus-host disease5. Thus, AML relapse risk might be more effectively reduced with T cells expressing receptors (TCRs) that target selected AML antigens6. We therefore isolated a high-affinity Wilms’ Tumor Antigen 1-specific TCR (TCRC4) from HLA-A2+ normal donor repertoires, inserted TCRC4 into Epstein–Bar virus-specific donor CD8+ T cells (TTCR-C4) to minimize graft-versus-host disease risk and enhance transferred T cell survival7,8, and infused these cells prophylactically post-HCT into 12 patients (NCT01640301). Relapse-free survival was 100% at a median of 44 months following infusion, while a concurrent comparative group of 88 patients with similar risk AML had 54% relapse-free survival (P = 0.002). TTCR-C4 maintained TCRC4 expression, persisted long-term and were polyfunctional. This strategy appears promising for preventing AML recurrence in individuals at increased risk of post-HCT relapse. Donor-derived, EBV-specific CD8+ T cells engineered to express a high-affinity WT1-specific TCR established persistent T cell responses that safely prevented post-HCT relapse in patients with high-risk AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0472-9

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 329

Metadata

Authors
Chapuis, A. G., Egan, D. N., Bar, M., Schmitt, T. M., McAfee, M. S., Paulson, K. G., Voillet, V., Gottardo, R., Ragnarsson, G. B., Bleakley, M., Yeung, C. C., Muhlhauser, P., Nguyen, H. N., Kropp, L. A., Castelli, L., Wagener, F., Hunter, D., Lindberg, M., Cohen, K., Seese, A., McElrath, M. J., Duerkopp, N., Gooley, T. A., & Greenberg, P. D.
Venue
Nature Medicine
Published
2019-06-24
Volume
25
Issue
7
Pages
1064-1072
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2952354682
Cited by
329
References
51
FWCI
16.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. https://app.cochat.ai/papers/10.1038/s41591-019-0472-9
The paper
Chapuis, A. G., Egan, D. N., Bar, M., Schmitt, T. M., McAfee, M. S., Paulson, K. G., Voillet, V., Gottardo, R., Ragnarsson, G. B., Bleakley, M., Yeung, C. C., Muhlhauser, P., Nguyen, H. N., Kropp, L. A., Castelli, L., Wagener, F., Hunter, D., Lindberg, M., Cohen, K., . . . Greenberg, P. D. (2019). T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nature Medicine. https://doi.org/10.1038/s41591-019-0472-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.